Summary: “If you want to invest in the mental health of people around the world, making us all more resilient to future crises, what can you do? Believe it or not, your best bet might be to fund drug development for psychedelic-assisted mental health treatments,” says Vox in an article exploring a new in-depth philanthropy report by Founders Pledge. The Founders Pledge research team analyzed data from trials of MDMA-assisted psychotherapy for PTSD and psilocybin-assisted therapy for depression, leading their research team to recommend funding psychedelic drug development from the non-profit organizations MAPS and Usona Institute.
Originally appearing here.
